Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M
The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
Br J Cancer. 2006 Jan 16;94(1):74-8. doi: 10.1038/sj.bjc.6602879.
Platinum-based combination chemotherapy has been proven to be superior to single-agent platinum in the treatment of relapsed ovarian cancer after a treatment-free interval of more than 6 months. A response rate of 41% was previously reported by our group using a combination of epirubicin, cisplatin and 5-FU in patients who relapsed within 12 months, we therefore assessed a similar, but more convenient combination of epirubicin, carboplatin and capecitabine in this phase-I/II trial. In total, 18 patients with recurrent epithelial ovarian carcinoma, who had not received more than two lines of chemotherapy and the treatment-free interval exceeded 6 months were treated with carboplatin AUC5, epirubicin 50 mg m(-2) and capecitabine at several dose levels on continuous 21 day cycles and 14 of 21 day cycles. Patients were assessed for toxicity and by CT and CA-125 for response. The overall response rate was 61.1%, with three complete and eight partial responses. Grade 3/4 haematological toxicity was seen in 10 out of 18 patients and caused dose reductions and treatment delays. The combination of epirubicin, carboplatin and capecitabine showed good activity but caused excessive toxicity. A phase-II trial using carboplatin and capecitabine is underway.
在超过6个月的无治疗间隔后，铂类联合化疗已被证明在复发性卵巢癌的治疗中优于单药铂类治疗。我们小组之前报告了在12个月内复发的患者中使用表柔比星、顺铂和5-氟尿嘧啶联合治疗的缓解率为41%，因此，在这项I/II期试验中，我们评估了一种类似但更方便的表柔比星、卡铂和卡培他滨联合方案。共有18例复发性上皮性卵巢癌患者，未接受过超过两线化疗且无治疗间隔超过6个月，接受了卡铂AUC5、表柔比星50 mg m(-2)和卡培他滨在几个剂量水平上的持续21天周期和14个21天周期的治疗。对患者进行毒性评估，并通过CT和CA-125评估反应。总缓解率为61.1%，其中3例完全缓解，8例部分缓解。18例患者中有10例出现3/4级血液学毒性，导致剂量减少和治疗延迟。表柔比星、卡铂和卡培他滨联合方案显示出良好的活性，但毒性过大。一项使用卡铂和卡培他滨的II期试验正在进行中。
